

# Evolva

**EverSweet** 

The announcement that Cargill has officially started producing EverSweet brings commercial reality to Evolva's stevia product, after years of R&D. In line with its new focus on a capital-light strategy, Evolva is not participating in a JV with Cargill, but will rather draw down a royalty stream. This allows a positive contribution to be made more rapidly, and significantly reduces the financial demands on Evolva. We adjust our model to account for this, and also trim our forecasts for FY18. As a result, our fair value moves to  $\in 0.60$  (from  $\in 0.65$ ).

Year end	Revenue (CHFm)	PBT* (CHFm)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/16	9.6	(35.9)	(6.8)	0.0	N/A	N/A
12/17	6.8	(40.9)	(7.0)	0.0	N/A	N/A
12/18e	8.8	(35.6)	(4.0)	0.0	N/A	N/A
12/19e	22.4	(28.4)	(3.2)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

# Delivering on the new strategy

CEO Simon Waddington outlined his new strategy with the H117 results: over time, Evolva has transformed itself from an R&D and technology platform with a number of products with potential, to an innovative ingredients company with a number of commercialised products. The new strategy favours remaining asset-light, thus preferring strategic partnerships – such as the one with Cargill – or using contract manufacturers for production of its ingredients. We believe the decision to take a royalty stream from Cargill is wise, as it significantly reduces the risks borne by Evolva, accelerates the timing of the positive contribution and improves the cash flow profile, yet only shaves 7% off our overall DCF value. The next significant catalyst should be the US Environmental Protection Agency (EPA) registration of nootkatone, which is expected by year-end.

# FY17 results

Total revenues of CHF6.8m were slightly below our forecast of CHF7.4m, with both product and R&D revenues lower than expected, and the net loss of CHF39.0m was above our forecast of CHF36.0m. Given the guidance for FY18 product revenues to at least double vs the CHF2.0m reported in 2017, we have cut our product sales assumptions for FY18 from CHF7.3m to CHF5.0m, and as a result we also cut sales forecasts for FY19, although to a much smaller extent.

# Valuation: Fair value of CHF0.60 per share

Our new fair value is CHF0.60/share (previously CHF0.65). We have updated our model to reflect the changes for EverSweet, namely that there will be a royalty stream that will contribute to the top line, rather than a 30% JV participation, and the capital investment required by Evolva will be much lower. We continue to value Evolva on a DCF basis with a 25-year model. We continue to model break-even in FY21, in line with management guidance.


#### FY17 results

Food & beverages

# 22 March 2018PriceCHF0.28Market capCHF216mNet cash at 31 December 2017 (CHFm)97.2

Shares in issue	770.2m
Free float	76%
Code	EVE
Primary exchange	SIX Swiss Ex
Secondary exchange	OTC US

#### Share price performance



#### **Business description**

Evolva is a Swiss high-tech fermentation company. It has a proprietary yeast technology platform, which it uses to create and manufacture high-value speciality molecules for nutritional and consumer products.

Next events	
Q118 results	May 2018
Analysts	
Sara Welford	+44 (0)20 3077 5700
Paul Hickman	+44 (0)20 3681 2501

consumer@edisongroup.com

Edison profile page

Evolva is a research client of Edison Investment Research Limited



# Valuation update

We detail our valuation in Exhibit 1. Our fair value falls slightly to CHF0.60/share (from CHF0.65/share previously). We have cut our FY18 sales forecasts for all the key products in light of the guidance that product revenues will at least double in FY18. As discussed above, our product revenue forecast for FY18 falls from CHF7.3m to CHF5.0m (this compares to CHF2.0m reported for FY17). Our FY19 product revenue forecast falls from CHF22.0m to CHF19.4m (excluding revenue from R&D partnerships and grants). Assuming successful commercialisation, we expect a significant ramp-up in sales of EverSweet (stevia) and nootkatone. Note that we still assume break-even occurs in FY21, in line with management guidance. We now expect the company to end FY20 with CHF4.7m of net debt. We believe by that stage, with the product revenues ramping up, Evolva ought to be able to raise debt to cover its financing needs.

Product	Value (CHFm)	Value/share (CHF)	
Stevia (royalty stream)	111.2	0.14	Launch date: 2018; peak sales: \$600m; royalty stream: 5%.
Resveratrol	29.8	0.04	Launched; peak sales: \$140m; likelihood of success 75%; margin: 30%.
Nootkatone	231.6	0.30	Launched; peak sales: \$150m; likelihood of success 75%*; margin: 40%.
Valencene	18.0	0.02	Launched; peak sales: \$10m; likelihood of success 90%; margin: 40%.
Capex	(24.7)	(0.03)	Includes investment of \$18m for commercialisation of stevia with Cargill
Net cash	97.2	0.13	Reported net cash at end FY17
Total	463.0	0.60	Using FY18 average number of shares throughout

Source: Edison Investment Research. Note: WACC = 12.5%. \*There is no developmental risk associated with nootkatone, but we have applied a risk adjustment due to uncertainty about the use of the product as an insect repellent.

We use a 25-year DCF valuation with a fade. Each product has varying peak sales, margins, rampup assumptions and probabilities of success, as detailed above. In each case, we reduce the R&D and operating expenditure after launch to reflect the lower level of investment required once the product is established on the market. We start to fade stevia in 2031 (year 13) and the other products in 2035 (year 17), and we also assume they become commoditised and their operating margins fall to the single digits, which is the level of commoditised food ingredients. Stevia remains a key product, at c 25% of our valuation, after adjusting for tax and capex, but note that we see greater value overall in nootkatone.

Our valuation purely reflects the products on which Evolva has chosen to concentrate, and we ascribe zero value to all other alliances/collaborations and other projects. We recognise that the latter do retain some residual value, but for the sake of conservatism we err on the side of caution. Management has stated that if commercial partners were to express an interest in these existing projects (for example saffron or santalol), it would consider them.

#### **EverSweet agreement**

Cargill and Evolva have reached a new agreement regarding their collaboration, which supersedes all previous agreements. Under the new agreement, Evolva will receive a royalty stream based on the sales of EverSweet. The royalty will be a mid-single digit percentage of sales. We have assumed 5%. The royalty will start to accrue as soon as EverSweet starts generating revenues. This will bring a positive contribution to Evolva significantly sooner than under previous agreements as, with a share of JV arrangement, Evolva would have had to bear its share of any start-up losses before seeing a positive contribution. We have left our assumptions unchanged for the underlying EverSweet market, and continue to expect peak sales of \$600m, reached in FY24. This results in a royalty stream of \$30m by FY24 (given a royalty rate of 5%), or \$21m on a net basis according to our assumptions. Previously we assumed operating margins of 30% and a 30% JV arrangement.



Furthermore, we previously applied a risk adjustment of 90% to stevia as it had not yet been launched, which we no longer apply. This resulted in a risk-adjusted net profit contribution of \$34m, which is only slightly higher than the royalty stream we now forecast.

The new agreement, however, also means Evolva is required to make a much lower financial contribution to the facility in Blair, Nebraska, which was previously forecast to cost \$45m over three years. Evolva must now contribute \$18m, payable over the next 12 months.

Overall therefore, the NPV of EverSweet has decreased from CHF167m to CHF111m, but the NPV of our capex has moved from -CHF47m to -CHF25m. The overall reduction to Evolva's NPV is 7%, and yet the risk profile has improved materially, as any risks associated with start-up/production issues will be entirely shouldered by Cargill, and no standalone project financing is required by Evolva (this was a condition of the old agreement).



#### Exhibit 1: Financial summary

CHF'000s	2015	2016	2017	2018e	2019e	2020
Year end 31 December	IFRS	IFRS	IFRS	IFRS	IFRS	IFR
PROFIT & LOSS						
Revenue	13,364	9,576	6,847	8,845	22,440	51,97
Cost of Sales	0	(2,951)	(4,698)	(3,177)	(9,815)	(25,212
Gross Profit	13,364	6,624	2,149	5,668	12,625	26,76
EBITDA	(30,305)	(33,965)	(37,599)	(35,247)	(27,967)	(13,613
Operating Profit (before GW and except.)	(31,947)	(36,078)	(39,774)	(35,976)	(28,678)	(35,976
ntangible Amortisation	(3,779)	(5,090)	(5,126)	(5,126)	(5,126)	(5,126
Exceptionals	0	0	0	0	0	(-)
Dperating Profit	(35,726)	(41,169)	(44,899)	(41,101)	(33,804)	(19,439
Vet Interest	(129)	497	(596)	389	278	17
Other financial income	0	(338)	(482)	0	0	
Profit Before Tax (norm)	(32,076)	(35,919)	(40,852)	(35,587)	(28,401)	(14,135
Profit Before Tax (FRS 3)	(35,855)	(41,009)	(45,977)	(40,713)	(33,526)	(19,261
Fax	4,067	5,160	7,023	4,886	4,023	2,31
Profit After Tax (norm)	(28,113)	(30,880)	(33,851)	(30,702)	(24,377)	(11,824
Profit After Tax (FRS 3)	(31,788)	(35,850)	(38,954)	(35,827)	(29,503)	(16,949
Average Number of Shares Outstanding (m)	401.3	452.8	482.1	770.6	770.6	(10,040
	101.0		102.1		110.0	770.
EPS - normalised (c)	(7.0)	(6.8)	(7.0)	(4.0)	(3.2)	(1.5
EPS - FRS 3 (c)	(7.9)	(7.9)	(8.1)	(4.6)	(3.8)	(2.2
Dividend per share (c)	0.0	0.0	0.0	0.0	0.0	0.
Gross Margin (%)	N/A	N/A	N/A	N/A	N/A	N//
EBITDA Margin (%)	N/A	N/A	N/A	N/A	N/A	N/2
Operating Margin (before GW and except.)	N/A	N/A	N/A	N/A	N/A	1 1/2
%)	N/A	N/A	N/A	N/A	N/A	N/
BALANCE SHEET						
Fixed Assets	143,457	141,356	132,125	138,876	139,669	134,49
ntangible Assets	131,940	130,256	124,487	119,361	114,236	109,11
Tangible Assets	8,431	7,522	5,208	5,085	5,003	4,95
Other fixed assets	3,086	3,578	2,430	14,430	20,430	20,43
Current Assets	88,780	56,880	107,697	70,435	47,374	41,12
Stocks	2,217	5,687	8,009	5,223	7,529	11,74
Debtors	2,785	2,139	1,831	2,181	3,689	8,54
Cash	83,228	47,517	97,185	57,473	26,574	8,94
Other current assets	550	1,537	673	5,558	9,582	11,89
Current Liabilities	(7,385)	(5,690)	(12,261)	(11,409)	(11,339)	(11,274
Creditors	(1,182)	(1,174)	(1,933)	(1,101)	(1,046)	(994
Short term borrowings	0	0	0	0	0	
Finance lease obligations	(969)	(978)	(781)	(781)	(781)	(781
Other current liabilities	(5,234)	(3,537)	(9,546)	(9,527)	(9,512)	(9,500
_ong Term Liabilities	(21,437)	(19,489)	(6,840)	(9,727)	(13,750)	(16,061
ong term borrowings	0	0	0	0	0	
Finance lease obligations	(4,134)	(3,564)	(2,400)	(2,400)	(2,400)	(2,400
Other long term liabilities	(17,303)	(15,925)	(4,440)	(7,327)	(11,350)	(13,661
Vet Assets	203,416	173,057	220,721	188,175	161,954	148,28
CASH FLOW						
Dperating Cash Flow	(31,353)	(33,551)	(35,194)	(27,496)	(24,546)	(17,153
Net Interest	(376)	(301)	(379)	389	278	17
Tax	0	0	0	0	0	
Capex	(1,865)	(947)	(582)	(606)	(630)	(655
Acquisitions/disposals	3,278	(210)	0	0	Ó	
inancing	59,956	Ó	86,457	0	0	
Dividends	0	0	0	0	0	
Other cash flow	(3,975)	(677)	(658)	(12,000)	(6,000)	
let Cash Flow	25,666	(35,686)	49,644	(39,713)	(30,898)	(17,63
Dpening net debt/(cash)	(57,191)	(83,228)	(47,516)	(97,185)	(57,473)	(26,575
			(,•.•)	(,)	(,)	(_0,010
	,	0	0	0	0	
HP finance leases initiated	0 371	0 (26)	0 24	0	0	

Source: Edison Investment Research, company data



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the <u>Financial Conduct Authority</u>. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Governe Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Inc [4794244]. <u>www.edisongroup.com</u>

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Evolva and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publication of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions to to certain categories of investment. The securities described in the Investment Research may not be eligible for sale in all jurisdictions to to certain categories of investment. This securities described in the United States by Edison US to institutional investors on to ectain categories of investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publisher's exclusion" from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding rotions. The information that we provide or that is derived from our website is not interded to be, and should not be construed and wisce. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this decourse the information the legal requirements' designed to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or utempt to effect, any transaction in a security. The research is sued for hey are solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed by any subscriber or prospective subscriber as position in any orrelate Section 20(2) (10), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell subscribe, or underwrite any securities mentioned or in the pipe of this document. This document is provided for inform

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US Sydney +61 (0)2 8249 8342 Level 12, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia